Literature DB >> 24733422

Complete remission of refractory, ulcerated, primary cutaneous CD30+ anaplastic large cell lymphoma following brentuximab vedotin therapy.

Nikolaos Patsinakidis1, Alexander Kreuter, Rose K C Moritz, Markus Stücker, Peter Altmeyer, Katrin Möllenhoff.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 24733422     DOI: 10.2340/00015555-1874

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


× No keyword cloud information.
  2 in total

Review 1.  Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.

Authors:  Garrett K Berger; Ali McBride; Stephanie Lawson; Kelsey Royball; Seongseok Yun; Kevin Gee; Irbaz Bin Riaz; Ahlam A Saleh; Soham Puvvada; Faiz Anwer
Journal:  Crit Rev Oncol Hematol       Date:  2016-11-21       Impact factor: 6.312

2.  Primary cutaneous CD 30 (+) ALK (-) anaplastic large cell lymphoma with dermoscopic findings: a case report.

Authors:  Tugba K Uzuncakmak; Necmettin Akdeniz; Ayse S Karadag; Secil Taskin; Ebru I Zemheri; Giuseppe Argenziano
Journal:  Dermatol Pract Concept       Date:  2017-01-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.